Terapevticheskii arkhivTerapevticheskii arkhiv0040-36602309-5342LLC Obyedinennaya Redaktsiya3366210.26442/00403660.2019.05.000255Review ArticleChronic kidney disease in rheumatoid arthritis patients: prevalence, risks factors, histopathological variantsChebotarevaN Vnatasha_tcheb@mail.ruGuliaevS V-AndrosovaT V-MilivanovaL U-I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Department of Internal, Occupational diseases and Rheumatology1505201991512913316042020Copyright © 2019, Consilium Medicum2019The present review is focused on risk factors of chronic kidney disease in rheumatoid arthritis (RA). According to recent data, the chronic kidney disease (CKD) in RA patients is more often than at patients without RA. It is closely associated with risk of cardiovascular disease and high mortality. Besides of general population risk factors of CKD, the activity of the disease is independent predictors of reduction in glomerular filtration rate less than 60 ml/min/1.73 m2. In the review, histopathological variants and mechanisms of CKD on basis of international experience are also considered. Suppression of inflammation by basic therapy of RA and biological therapy have changed outcomes RA, prevalence, and structure of kidney involvement in recent years.rheumatoid arthritisamyloidosischronic glomerulonephritischronic kidney diseasebasic therapyревматоидный артритамилоидозхронический гломерулонефритхроническая болезнь почекбазисная терапия[Waldburger J.M, Firestein G.S. Rheumatoid arthritis: B. Epidemiology, pathology, and pathogenesis. In: Klippel J.H (ed). Primeron the Rheumatic Diseases, 13th edn. New York, NY: Springer, 2008:122-132.][Carmona L, Cross M, Betal W. Rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2010;24:733-74.][Etiology and pathogenesis of rheumatoid arthritis. In: Firestein G.S, Kelley W.N (eds). Kelley’s Textbook of Rheumatology, 8th edn. Philadelphia, PA: Saunders/Elsevier, 2009:1035-86.][Насонов Е.Л. Фармакотерапия ревматоидного артрита: новая стратегия, новые мишени. Научно - практическая ревматология. 2017;55(4):409-19. https://doi.org/10.14412/1995-4484-2017-409-419][Listing J, Kekow J, Manger B, et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis. 2015;74:415-21.][Hickson L.J, Crowson C.S, Gabriel S.E, et al. Development of reduced kidney function in rheumatoid arthritis. Am J Kidney Dis. 2014;63:206-13.][Tokoroyama T, Ando M, Setoguchi K, Tsuchiya K, Nitta K. Prevalence, incidence and prognosis of chronic kidney disease classified according to current guidelines: a large retrospective cohort study of rheumatoid arthritis patients. Nephrol Dial Transplant. 2016;0:1-8. doi: 10.1093/ndt/gfw315][Foster M.C, Rawlings A.M, Marrett E, et al. Potential effects of reclassifying CKD as a coronary heart disease risk equivalent in the US population. Am J Kidney Dis. 2014;63:753-60.][Оранский С.П. Хроническая болезнь почек при ревматоидно артрите: ассоциация с сердечно - сосудистым риском. Фундаментальные исследования. 2013;12(2):285-8.][Батюшин М.М., Выставкина Е.А. Факторы риска развития и прогрессирования хронической болезни почек у больных ревматоидным артритом. Современные проблемы науки и образования. 2011;5. URL: http://www.science-education.ru/ru/article/view?id=4871][Ребров А.П., Тяпкина М.А., Волошинова Е. В. Субклиническое поражение почек у пациентов с ревматоидным артритом. Лечащий врач. 2012;4:40-2.][Kim H.W, Lee C.K, Cha H.S, Choe J.Y, Park E.J, Kim J. Effect of anti - tumor necrosis factor alpha treatment of rheumatoid arthritis and chronic kidney disease. Rheumatol Int. 2015;35(4):727-34. doi: 10.1007/s00296-014-3146-4][Chiu H.Y, Huang H.L, Li C.H, Chen H.A, Yeh C.L, Chiu S.H, Lin W.C, Cheng Y.P, Tsai T.F, Ho S.Y. Increased Risk of Chronic Kidney Disease in Rheumatoid Arthritis Associated with Cardiovascular Complications - A National Population-Based Cohort Study. PLoS One. 2015;25,10(9):e0136508. doi: 10.1371/journal.pone.0136 508][Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т., Мартынов А.И., Яхно Н.Н., Арутюнов Г.П., Алексеева Л.И., Абузарова Г.Р., Евсеев М.А., Кукушкин М.Л., Копенкин С.С., Лила А.М., Лапина Т.Л., Новикова Д.С., Попкова Т.В., Ребров А.П., Скоробогатых К.В., Чичасова Н.В. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно - практическая ревматология. 2018;56:1-29. https://doi.org/10.14412/1995-4484-2018-1-29][Cannon C, Curtis S, Fitz-Gerald G, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long - term (MEDAL) programme: a randomised comparison. Lancet. 2006;368(9549):1771-81. doi: 10.1016/S0140-6736(06)69666-9][Nissen S.E, Yeomans N.D, Solomon D.H, et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016 Dec 29;375 (26):2519-29. doi: 10.1056/NEJMoa1611593. Epub 2016 Nov 13][Möller B, Pruijm M, Adler S, Scherer A, Villiger P.M, Finckh A. Chronic NSAID use and long - term decline of renal function in a prospective rheumatoid arthritis cohort study. Ann Rheumatic Disease. 2013:74. http://dx.doi. org/10.1136/ annrheumdis-2013-204078][Karie S, Gandjbakhch F, Janus N, Launay-Vacher V, Rozenberg S, Mai Ba C.U, Bourgeois P, Deray G. Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study. Rheumatology (Oxford). 2008;47:350-4.][Hickson L.J, Crowson C.S, Gabriel S.E, et al. Development of reduced kidney function in rheumatoid arthritis. Am J Kidney Dis. 2014;63:206.][Huerta C, Castellsague J, Varas-Lorenzo C, Garcia Rodriguez L.A. Nonsteroidal anti - inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis. 2005 Mar;45(3):531-9. doi: 10.1053/j.ajkd.2004.12.005][Kochi M, Kohagura K, Shiohira Y, Iseki K, Ohya Y. Inflammation as a Risk of Developing Chronic Kidney Disease in Rheumatoid Arthritis. PLOS ONE. 2016. doi: 10.1371/journal.pone.016022][Toblli J.E, Bevione P, Di Gennaro F, Madalena L, Cao G, Angerosa M. Understanding the mechanisms of proteinuria: therapeutic implications. Int J Nephrol. 2012:546039. doi: 10.1155/2012/546039][Hemmelgarn B.R, Manns B.J, Lloyd A, et al. Relation between kidney function, proteinuria, and adverse outcomes. J Amer Med Association. 2010;303(5):423-9.][Boers M, Croonen A.M, Dijkmans B.A, et al. Renal findings in rheumatoid arthritis: clinical aspects of 132 necropsies. Ann Rheum Dis. 1987;46:658-63.][Shankar A, Sun L, Klein B.E, Lee K.E, Muntner P, Nieto F.J, et al. Markers of inflammation predict the long - term risk of developing chronic kidney disease: a population - based cohort study. Kidney Int. 2011;80(11):1231-8. doi: 10.1038/ki. 2011.283][Киселева А.Г., Орлова Г.М., Бердникова И.А., Фереферова Н.М. Хроническая болезнь почек у больных ревматоидным артритом. Сибирский медицинский журнал. 2007;7:90-2.][Nakahara C, Kanemoto K, Saito N, Oyake Y, Kamoda T, Nagata M, et al. C-reactive protein frequently localizes in the kidney in glomerular diseases. Clin Nephrol. 2001;55(5):365-70.][Schwedler S.B, Guderian F, Dämmrich J, Potempa L.A, Wanner C. Tubular staining of modified C-reactive protein in diabetic chronic kidney disease. Nephrol Dial Transplant. 2003;18(11):2300-7.][Li Z, Chung A.C.K, Zhou L, Huang X.R, Liu F, Fu P, et al. C-reactive protein promotes acute renal inflammation and fibrosis in unilateral ureteral obstructive nephropathy in mice. Laboratory Investigation [Article]. 2011;91(6):837-51. doi: 10.1038/labinvest.2011.42][Galarraga B, Khan F, Kumar P, Pullar T, Belch J.J. C-reactive protein: the underlying cause of microvascular dysfunction in rheumatoid arthritis. Rheumatology (Oxford). 2008;47(12):1780-4.][Tapia E, Sánchez-González D.J, Medina-Campos O.N, Soto V, Avila-Casado C, Martínez-Martínez C.M, et al. Treatment with pyrrolidine dithiocarbamate improves proteinuria, oxidative stress, and glomerular hypertension in overload proteinuria. Am J Physiol Renal Physiol. 2008;295(5):1431-9. doi: 10.1152/ajprenal.90201.2008][Makino H, Yoshinaga Y, Yamasaki Y, et al. Renal involvement in rheumatoid arthritis: analysis of renal biopsy specimens from 100 patients. Mod Rheumatol. 2002;12:148-54.][Helin H.J, Korpela M.M, Mustonen J.T, Pasternack A.I. Renal biopsy findings and clinicopathologic correlations in rheumatoid arthritis. Arth Rheum. 1995;38(2):242-7.][Мухин Н.А. Амилоидоз почек: вопросы клиники и патогенеза: Автореф. дис. … докт. мед. наук. М., 1981.][Козловская Л.В. Амилоидоз. Терапевтический архив. 1998;6:62-70.][Саркисова И.А. Факторы риска развития и прогрессирования АА-амилоидоза у больных ревматоидным артритом: Автореф. дис…. канд. мед. наук. М., 2005.][Козловская Л.В., Варшавский В.А., Чегаева Т.В., Проскурнева Е.П., Рамеев В.В. Амилоидоз: современный взгляд на проблему. Практическая нефрология. 1998;2:16-23.][Pollak V.E, Pirani C.L, Steck I.E, Kark R.M. The kidney in rheumatoid arthritis: studies by renal biopsy. Arthritis Rheum. 1962;5:1-9.][Gertz M.A, Kyle R.A. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine (Baltimore). 1991;70:246.][Berglund K, Keller C, Thysell H. Alkylating cytostatic treatment in renal amyloidosis secondary to rheumatic disease. Ann Rheum Dis. 1987;46:757.][Immonen K, Finne P, Gronhagen-Riska C, Pettersson T, Kautiainen H, Hakala M. Steep decline in the incidence of renal replacement therapy for amyloidosis associated with inflammatory rheumatic diseases. Scand J Rheumatol. 2009;38:403.][Góis M, Carvalho F, Sousa H, Ferreira A.C, Sousa J, Nolasco F. Renal involvement in rheumatoid arthritis: analysis of 53 renal biopsies. Port J Nephrol. 2017. Hypert.31 (1).][Horii Y, Iwano M, Hirata E, Shiiki M, Fujii Y, Dohi K, Ishikawa H. Role of interleukin-6 in the progression of mesangial proliferative glomerulonephritis. Kidney Int Suppl. 1993;39:71-5.][Salomon M.I, Gallo G, Poon T.P, Goldbalt M.V, Tchertkoff V. The kidney in rheumatoid arthritis. Nephron. 1974;12:297310.][Ramirez G, Lambert R, Bloomer A. Renal pathology in patients with rheumatoid arthritis. Nephron. 1981;29:124-6.][Nakano M, Ueno M, Nishi S, Shimada H, Hasegawa H, Watanabe T, Kuroda T, Sato T, Maruyama Y, Arakawa M. Analysis of renal pathology and drug history in 158 Japanese patients with rheumatoid arthritis. Clin Nephrol. 1998;50:154-60.][Yoshida K, Morozumi K, Sunganuma T, Aoki J, et al. Clinicopathological study of nephropathy in patients with rheumatoid arthritis. Ryumachi. 1991;31:14-21.][Nagahama K, Matsushita H, Hara M, Ubara Y, Hara S, Yamada A. Bucillamine induces membranous glomerulonephritis. Am J Kidney Dis. 2002;39(4):706-12.][Horak P, Smrzova A, Krejci K, Tichy T, Zadrazil J, Skacelova M. Renal manifestations of rheumatic diseases. A review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013;157(2):98-104. doi: 10.5507/bp.2013.042][Sumida K, Molnar M.Z, Potukuchi P.K, Hassan F, Thomas F, Yamagata K, Kalantar-Zadeh K, Kovesdy CP. Treatment of rheumatoid arthritis with biologic agents lowers the risk of incident chronic kidney disease. Kidney Int. 2018;93(5):1207-16. doi: 10.1016/j.kint.2017.11.025][Barnabe C, Martin B.J, Ghali W.A. Systematic review and meta - analysis: anti - tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2011;63(4):522-9. doi: 10.1002/acr.20371][Roubille C, Richer V, Starnino T, Mc Court C, Mc Farlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B. The effects of tumour necrosis factor inhibitors, methotrexate, non - steroidal anti - inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta - analysis. Ann Rheum Dis. 2015;74(3):480-9. doi: 10.1136/annrheumdis-2014-206624][Popkova T.V, Novikova D.S, Gasparyan A.Y, Nasonov E.L. Cardiovascular effects of methotrexate in rheumatoid arthritis. Curr Med Chem. 2015;22:1903-10.][Удачкина Е.В., Новикова Д.С., Попкова Т.В. и др. Динамика липидных параметров крови у больных ревматоидным артритом на фоне комбинированной терапии тоцилизумабом и метотрексатом в сравнении с монотерапией метотрексатом при 24-недельном наблюдении. Рациональная фармакотерапия в кардиологии. 2015;11(5):510-6.][Fernández-Nebro A, Tomero E, Ortiz-Santamaría V, Castro M.C, Olivé A, de Haro M, Portales R.G, González-Mari M.V, Laffón A, García-Vicuña R. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Am J Med. 2005;118(5):552-6.][Nakamura T, Higashi S, Tomoda K, Tsukano M, Shono M. Effectiveness of etanercept vs cyclophosphamide as treatment for patients with amyloid A amyloidosis secondary to rheumatoid arthritis. Rheumatology (Oxford). 2012;51(11):2064-9. doi: 10.1093/rheumatology/kes190][Gottenberg J.E, Merle-Vincent F, Bentaberry F, Allanore Y, Berenbaum F, Fautrel B, Combe B, Durbach A, Sibilia J, Dougados M, Mariette X. Anti - tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum. 2003;48(7):2019-24.][Novikova D.S, Popkova T.V, Nasonov E.L. The effect of anti-B-cell therapy on the development of atherosclerosis in patients with rheumatoid arthritis. Cur Pharm Des. 2012;18:1512-8.]